Zhiyong Quan

Zhiyong Quan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
XMXiaoli Meng
Xiaoli Meng
ZQZhiyong Quan
Zhiyong Quan
LFLinni Fan
Linni Fan
MZMingru Zhang
Mingru Zhang
GLGuiyu Li
Guiyu Li
FKFei Kang
Fei Kang

1 September 2026 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
XGXiaoli Gou
Xiaoli Gou
THTingting Han
Tingting Han
TYTengyue Yang
Tengyue Yang
LYLi Yang
Li Yang
FKFei Kang
Fei Kang
ZQZhiyong Quan
Zhiyong Quan
Background: MRI exhibits inherent limitations for preoperative TNM staging of rectal cancer, partially limiting its clinical utility. This head-to-head study compared the performance of ⁶⁸Ga-FAPI-04 PET/CT and MRI for stratified preoperative TNM staging of rectal cancer. We further assessed the predictive efficacy of quantitative PET/CT parameters for differentiating T stages, and explored whether these quantitative indicators could act as an adjunct to MRI staging. Methods: This single-center retrospective study recruited 81 patients diagnosed with rectal cancer, all of whom received whole-abdominal MRI and whole-body ⁶⁸Ga-FAPI-04 PET/CT scanning. Multiple quantitative metabolic parameters, including SUVmax, SUVmean, MTV, TLU, and TBR, were extracted for subsequent analyses. McNemar’s test was adopted to compare the sensitivity, specificity and diagnostic accuracy of the two imaging modalities in preoperative TN staging. Regarding M staging evaluation, the detection performance of metastatic lesions was only compared within the overlapping abdominopelvic scanning range of the two imaging protocols. All lesions located outside this overlapping coverage zone were merely described qualitatively without inter-group comparison. Spearman correlation analysis and binary logistic regression were applied to explore the correlations between T stage and the aforementioned quantitative parameters. ROC and DCA curves were plotted to quantify diagnostic performance and corresponding clinical net benefit, respectively. Results: In T2-stage assessment, MRI demonstrated superior specificity and accuracy relative to PET/CT (85.25% vs. 59.02%; 86.42% vs. 62.96%). Similarly, MRI yielded a greater overall accuracy for T3 staging(83.95% vs. 69.14%). All the above intergroup differences reached statistical significance (all P < 0.001). For N1 nodal staging, PET/CT showed higher specificity (87.72% vs. 73.68%, P = 0.039) and accuracy (80.25% vs. 62.96%, P = 0.004) compared with MRI. Within the overlapping abdominopelvic scan range, PET/CT identified more metastatic lesions than MRI (6 versus 3). Additionally, PET/CT detected 14 metastatic lesions that were invisible on MRI beyond the abdominopelvic coverage area. Distinct values of all PET/CT quantitative parameters were observed across different T categories (all P < 0.001). TLU presented the most prominent positive linear association with T stage ( r = 0.752, P < 0.001). Binary logistic regression analysis preliminarily indicated a statistical correlation between TLU and T3 disease status (all P < 0.05). When distinguishing T1/T2 low-stage tumors from T3 lesions, TLU generated an AUC value of 0.889. The optimal threshold of 64.354 provided a sensitivity of 81.00% and specificity of 86.20%. Combined parameter groups including SUVmax+TLU and ADC+TLU produced AUCs of 0.883 and 0.935, respectively. At their respective optimal cut-off values, both combined parameter groups yielded a sensitivity of 78.60% and specificity of 93.10%. Decision curve analysis further indicated that the ADC+TLU combined parameter group provided the maximum net clinical benefit throughout the 0–50% probability threshold interval. Conclusion: MRI remains the primary imaging modality for local T-staging evaluation, especially for T2 and T3 rectal lesions. ⁶⁸Ga-FAPI-04 PET/CT achieves superior diagnostic performance in N1 nodal staging and the identification of distant metastases. Quantitative indicators derived from ⁶⁸Ga-FAPI-04 PET/CT, particularly TLU and multiple combined indicators, preliminarily indicate favorable diagnostic ability and carry potential auxiliary value to assist MRI in differentiating distinct T-stage subgroups.

3 March 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
MWMin Mmed Wang
Min Mmed Wang
KXKeke Bm Xin
Keke Bm Xin
JWJing Wang
Jing Wang
FKFei Kang
Fei Kang
ZQZhiyong Quan
Zhiyong Quan
A 52-year-old man with multiple scalp nodules for more than 30 years and a right occipital mass that had been progressively enlarging for the past 2 years and rupturing and draining for more than 6 months was pathologically confirmed to be secondary malignant proliferating trichilemmal cyst (MPTC). 18 F-FDG PET/CT showed active glucose metabolism in the scalp lesion and similar hypermetabolism in the dorsal and right iliac spine skin nodules. This case demonstrates the significant advantages of 18 F-FDG PET/CT whole-body imaging in evaluating malignant proliferating trichilemmal cyst, a rare disease.

8 December 2021 in Research Square
Verified
Preprint
Open access
PDF file
WZWeiwei Zhao
Weiwei Zhao
JYJing Yu
Jing Yu
YBYuyu Bi
Yuyu Bi
YHYi Huan
Yi Huan
YZYuanqiang Zhu
Yuanqiang Zhu
YYYong Yang
Yong Yang
Objectives Dynamic contrast-enhanced MRI (DCE-MRI) with Extended Tofts Linear (ETL) model has been used in tissue and tumor evaluation. However, its reliability and reproducibility in pancreatic evaluation has been unclear. It is also unclear whether pancreatic DCE-MRI pharmacokinetic parameters were consistent and stable among different pancreatic regions, ages and genders. Methods Pancreatic pharmacokinetic parameters of 54 volunteers were calculated using DCE-MRI with ETL model. Firstly, Intra- and inter-observer reproducibility was evaluated using intra-class correlation coefficient (ICC) and coefficient of variation (CoV). Secondly, subgroup evaluation of pancreatic DCE-MRI pharmacokinetic parameters was performed. 54 subjects were divided into three groups in virtue of pancreatic region, three groups according to age, two groups according to gender, which pharmacokinetic parameters among and between different groups were calculated and compared. Results There was excellent agreement and low variability of intra- and inter-observer to pancreatic DCE-MRI pharmacokinetic parameters. The intra- and inter-observer ICCs of Ktrans, kep, ve, vp were 0.971, 0.952, 0.959, 0.944 and 0.947, 0.911, 0.978, 0.917, respectively. The intra- and inter-observer CoVs of Ktrans, kep, ve, vp were 9.98%, 5.99%, 6.47%, 4.76% and 10.15%, 5.22%, 6.28%, 5.40%, respectively. There were no significant differences of Ktrans, kep among different pancreatic regions, among different age groups, between male and female groups (P all > 0.10). Only, pancreatic ve of old group was higher than that of young and middle-aged groups (P = 0.042, 0.001), and vp of pancreatic head was higher than that of pancreatic body and tail (P = 0.014, 0.043). Conclusions DCE-MRI with ETL model is reliable and reproducible for quantitative assessment of pancreatic pharmacokinetic parameters. ve varies with age and vp varies with pancreatic region, which can provide guidance for the selection of normal reference in the pharmacokinetics study of pancreatic diseases.